Added to YB: 2026-06-12
Pitch date: 2026-06-10
HRMY [neutral]
Harmony Biosciences Holdings, Inc.
-1.1%
current return
Author Info
No bio for this author
Company Info
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States.
Market Cap
$2.1B
Pitch Price
$35.59
Price Target
N/A
Dividend
N/A
EV/EBITDA
7.28
P/E
14.31
EV/Sales
1.75
Sector
Pharmaceuticals
Category
growth
GS Healthcare Conference – Recap part 1 (Day 2) - Harmony Biosciences Holdings, Inc.
HRMY (overview): Cash-rich CNS name at $34.20, built on WAKIX franchise (IP to March 2030 w/ pediatric exclusivity) targeting $1B narcolepsy franchise. Pipeline torque via orexin-2 agonist VP-205 (NT1/NT2/IH, SAD data imminent), WAKIX GR NDA Q2'26 PDUFA Q1'27, EPX-100 Phase 3 data 2027. Active BD.
Read full article (1 min)